IAVI

0

KAVI Institute of Clinical Research launches IAVI W001 study

The first volunteer enrolled in IAVI-W001 receives the study vaccine.

KAVI Institute of Clinical Research enrolled the first volunteer to start a phase 1 clinical trial to test a novel HIV vaccine candidate, BG505 SOSIP.664 gp140.

The study dubbed the International AIDS Vaccine Initiative W001 (IAVI W001) is aimed at assessing the safety of the candidate and to determine if vaccination induces the human immune system to produce proteins known as neutralizing antibodies (NAbs).

Subscribe to IAVI